[68Ga]Ga-OncoACP3-DOTA 在前列腺癌患者中的首人体内动力学、药代动力学及辐射剂量学研究
该研究纳入7例转移性去势抵抗性前列腺癌患者,评估新型ACP3靶向放射性配体[68Ga]Ga-OncoACP3-DOTA的体内动力学、药代动力学及辐射剂量学。结果显示该药物呈双肾及肝胆排泄,转移灶摄取随时间增加且肿瘤/本底比值持续升高,药代动力学符合不可逆结合的2组织室模型。平均有效剂量为0.0192 mSv/MBq,标准注射2.5 MBq/kg时有效剂量为3.50 mSv,骨髓、肾脏和肝脏吸收剂量最高,唾液腺可忽略。
要点
- 转移灶摄取随时间增加,肿瘤/本底比值持续升高,支持延迟显像
- 平均有效剂量0.0192 mSv/MBq,标准注射2.5 MBq/kg时为3.50 mSv
- 骨髓、肾脏、肝脏吸收剂量最高,唾液腺吸收剂量可忽略
核心结论
- [68Ga]Ga-OncoACP3-DOTA药代动力学良好,延迟时间点肿瘤摄取和肿瘤/本底比值增加,提示延迟显像的潜在获益。
- 剂量学特征良好,有效剂量低于许多PSMA靶向放射性药物,唾液腺摄取可忽略,可能减少放射性药物治疗期间的副作用。
- 仍需未来研究评估其临床价值。
研究设计与样本
- 前瞻性首人体内研究,纳入7例转移性去势抵抗性前列腺癌患者,静脉注射[68Ga]Ga-OncoACP3-DOTA后行动态或多时间点PET/CT。
- 5例患者行胸部早期动态扫描,6例患者行注射后第一小时内动态全身PET扫描,5例患者行额外延迟时间点全身PET扫描(中位3.2小时)。
- 对正常器官和转移灶的体积感兴趣区测定SUV,计算摄取动力学和肿瘤/本底比值,并进行多室药代动力学建模和剂量学计算。
主要发现
- [68Ga]Ga-OncoACP3-DOTA在大多数器官中摄取下降,仅排泄相关器官例外,前列腺摄取保持稳定;呈双肾及肝胆排泄。
- 血液动力学下降可用三指数函数良好拟合;转移灶摄取从早期到延迟时间点增加,肿瘤/本底比值强烈升高。
- 药代动力学建模显示,不可逆结合的2组织室模型最适合描述转移灶摄取;骨转移与淋巴结转移的K1和Ki值存在显著差异。
关键数值与推荐
- 平均有效剂量为0.0192 mSv/MBq,标准注射2.5 MBq/kg时有效剂量为3.50 mSv。
- 吸收剂量最高位于骨髓(0.0913 mGy/MBq)、肾脏(0.0657 mGy/MBq)和肝脏(0.0563 mGy/MBq),唾液腺为0.0135 mGy/MBq。
- 药代动力学建模依据Akaike信息准则评估,剂量学计算使用MIRDfit和MIRDcalc,时间积分活度系数缩放至ICRP 133成年男性参考体模。
临床怎么用
- 该药物支持延迟显像策略,尤其适用于高灵敏度PET系统或半衰期较长的同位素标记。
- 较低的有效剂量和可忽略的唾液腺摄取可能有利于后续放射性配体治疗时减少副作用。
局限性
- 样本量小(7例患者),各扫描子集例数有限(5–6例)。
- 原文未报告诊断性能、治疗响应或长期随访数据。
- 作者指出仍需未来研究评估其临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to investigate the dynamics, pharmacokinetic characteristics, and radiation dosimetry of [68Ga]Ga-OncoACP3-DOTA, a novel prostatic acid phosphatase (ACP3)-targeted radioligand, in patients with metastatic castration-resistant prostate cancer. Methods: Seven patients with metastatic castration-resistant prostate cancer had dynamic or multiple-time-point PET/CT scans after intravenous injection of [68Ga]Ga-OncoACP3-DOTA available. Five patients had early dynamic scans over the thorax, and 6 had dynamic whole-body PET scans during the first hour after injection. Five patients underwent an additional late-time-point whole-body PET scan (median, 3.2 h postinjection). SUVs for volumes of interest were determined for normal organs and metastases, and uptake dynamics and tumor-to-background ratios were calculated. Pharmacokinetic modeling was performed for multiple compartment models and evaluated in accordance with the Akaike information criterion. Dosimetry calculations were performed using MIRDfit and MIRDcalc, with time-integrated activity coefficients scaled to the International Commission on Radiological Protection 133 Adult Male Reference Phantom. Results: [68Ga]Ga-OncoACP3-DOTA displayed declining uptake in most organs, except for organs involved in excretion, and stable uptake was observed only in the prostate. Dual renal and hepatobiliary excretion was noted. Declining blood kinetics were well-fitted by a triexponential function. Metastases showed an increase in uptake from early to late time points, with intensely increasing tumor-to-background ratios. Pharmacokinetic modeling indicated that a 2-tissue compartment model with irreversible binding was most appropriate for describing metastatic uptake. Bone and lymph node metastases exhibited significant differences in K 1 and K i values. The mean effective dose was 0.0192 mSv/MBq, resulting in an effective dose of 3.50 mSv for a standard injection of 2.5 MBq/kg. The highest absorbed doses were observed in bone marrow (0.0913 mGy/MBq), kidneys (0.0657 mGy/MBq), and liver (0.0563 mGy/MBq), whereas salivary glands showed a negligible absorbed dose (0.0135 mGy/MBq). Conclusion: [68Ga]Ga-OncoACP3-DOTA demonstrated favorable pharmacokinetics with increasing tumor uptake and tumor-to-background ratios at later time points, suggesting potential benefits for delayed imaging, especially with high-sensitive PET systems or radiolabeling with isotopes with longer half-lives. The dosimetry profile was favorable, with a lower effective dose compared with many prostate-specific membrane antigen-targeted radiopharmaceuticals and negligible salivary gland uptake, potentially reducing side effects during radiopharmaceutical therapy. Future studies are warranted to evaluate its clinical value.
引用
- Brosch-Lenz J, Büther F, Oehler S, et al. Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer. J Nucl Med. 2026. PMID: 42061944. doi:10.2967/jnumed.125.271933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。